|
Frank Vinluan
@
frankvinluan
North Carolina
|
|
Business journalist in Research Triangle Park on @Xconomy's biotech team covering pharma, medtech, agtech. 71% free throw shooter. Genesis: Album 9, track 11.
|
|
|
4.355
Tweetovi
|
601
Pratim
|
1.223
Osobe koje vas prate
|
| Tweetovi |
|
Frank Vinluan
@frankvinluan
|
4. velj |
|
|
||
| Frank Vinluan proslijedio/la je tweet | ||
|
Xconomy
@Xconomy
|
4. velj |
|
.@Passage_Bio Plans IPO as Three Gene Therapies Approach the Clinic
- by @sarahdc
xconomy.com/new-york/2020/… $PASG
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
3. velj |
|
ICYMI, @aimmune won FDA approval Friday for #Palforzia, a peanut allergy therapy. The FDA decision covers kids 4-17 yrs.old... xconomy.com/san-francisco/… $AIMT
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
1. velj |
|
#Palforzia carries an $890 a month wholesale price before any rebates or discounts. But @aimmune says it will offer payment assistant programs that could reduce the cost to as low as $20 a month. The new drug is expected to launch in coming weeks.
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
1. velj |
|
The @aimmune #immunotherapy is not a cure. It's meant to reduce sensitivity so that a reaction to accidental peanut exposure is less severe. But #Palforzia comes with a warning that it can cause side effects, including anaphylaxis.
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
1. velj |
|
First FDA approval for a #peanutallergy therapy goes to @aimmune. The decision for #Palforzia covers kids 4-17 who have a confirmed peanut allergy diagnosis xconomy.com/san-francisco/… $AIMT
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
31. sij |
|
When it comes to #CRISPR, size matters. Here's why @mammothbiosci thinks the smaller size of Cas14 gives it advantages for developing new drugs and diagnostics xconomy.com/san-francisco/…
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
30. sij |
|
Black Diamond Therapeutics sold more shares than initially planned, and topped its targeted price range, raising $201M from its #IPO. Proceeds will support a Phase 1-ready #cancer drug, as well as further development of its pipeline xconomy.com/boston/2020/01… $BDTX
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
29. sij |
|
This @AcceleronPharma drug didn't pan out treating a rare blood disorder or chronic kidney disease. But with positive topline Phs 2 data in #pulmonaryarterialhypertension, some now see blockbuster potential. $XLRN shares shot up 50% Tues. xconomy.com/boston/2020/01… #PAH
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
28. sij |
|
RA Capital led the $50M Series A round for Quench Bio, a discovery-stage #biotech #startup researching a new approach to treating inflammatory disorders xconomy.com/boston/2020/01…
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
27. sij |
|
|
||
|
Frank Vinluan
@frankvinluan
|
24. sij |
|
Epizyme’s #cancer drug wins accelerated FDA approval, the first for the company and the first nod for a drug treating the rare soft-tissue cancer epithelioid sarcoma... xconomy.com/boston/2020/01… $EPZM
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
23. sij |
|
FDA rejection letters typically stay private. Correspondence between the agency and @Sarepta shed light on the thinking that led to the rejection and subsequent approval of Duchenne muscular dystrophy drug #golodirsen xconomy.com/boston/2020/01… $SRPT
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
23. sij |
|
Yes, that's right.
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
22. sij |
|
This new Eli Lilly facility will be built in a part of #RTP that had been an R&D campus for GlaxoSmithKline and its predecessors for decades. GSK sold the site in 2017, but still leases a small portion. twitter.com/ncbiotech/stat…
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
21. sij |
|
ICYMI, Revolution Medicines filed for a $100M #IPO late last week. Lead #cancer drug is in Phase 1 testing under partnership with Sanofi... xconomy.com/san-francisco/… $RVMD $SNY
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
18. sij |
|
Details about that deal and more are in Revolution Medicines' S-1 filing: sec.gov/Archives/edgar… $RVMD
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
18. sij |
|
Revolution is the company that acquired Warp Drive Bio in 2018, biotech that was also developing RAS #cancer drugs. xconomy.com/san-francisco/… $RVMD
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
18. sij |
|
It got its start in 2015, spinning out of VC firm @ThirdRockV. #Cancer was not Revolution's initial target, but that focus developed as the University of Illinois technology that formed the basis of the #startup led it to a way to drug RAS. xconomy.com/san-francisco/… $RVMD
|
||
|
|
||
|
Frank Vinluan
@frankvinluan
|
18. sij |
|
|
||